{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-002538","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.579495+00:00","generated_at":"2026-06-27T02:56:01.339019+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kodiak Sciences Q4 net loss $93.2M; wet AMD pivotal trial misses primary endpoint","bullets":["Phase 2b/3 KSI-301 study in wet AMD did not meet non-inferiority vs aflibercept for extended dosing.","59% of KSI-301 patients achieved 5-month dosing; safety profile acceptable with no new signals.","Q4 net loss $93.2M ($1.79/share) vs $46.6M a year ago; full year net loss $267.0M.","R&D expenses $75.6M in Q4, up from $37.4M, driven by clinical trial and manufacturing costs.","Cash and equivalents $731.5M; BEACON RVO top-line data expected Q3 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-002538","json":"https://secwatch.observer/filing/0000950170-22-002538.json","markdown":"https://secwatch.observer/filing/0000950170-22-002538.md","text":"https://secwatch.observer/filing/0000950170-22-002538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022002538/0000950170-22-002538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022002538/kod-20220301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:56:01.339019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}